20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vogenx Inc Common Stock (VOGX) operates in the BIOTECHNOLOGY industry and is headquartered in Raleigh, United States with about 4 employees. Its market capitalization is roughly $301 million. In the fiscal year ended 2025-12-31, VOGX reported $0M in revenue and ($1M) in net income.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($2M) | ($1M) | ($2M) |
| Operating Margin % | — | — | — |
| Net Income | ($2M) | ($1M) | ($2M) |
| Net Margin % | — | — | — |
| EBITDA | ($2M) | ($1M) | ($2M) |
| Earnings Per Share (EPS) | — | $-0.10 | $-0.16 |
| Shares Outstanding (M) | 14M | 14M | 14M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | $0M | $0M | $0M | $0M |
| Operating Margin % | — | — | — | — |
| Net Income | $0M | $0M | $0M | $0M |
| Net Margin % | — | — | — | — |
| EBITDA | $0M | $0M | $0M | $0M |
| Earnings Per Share (EPS) | $-0.03 | $-0.03 | — | — |
| Shares Outstanding (M) | 14M | 14M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($1M) | ($1M) | ($2M) |
| Free Cash Flow (FCF) | ($1M) | ($1M) | ($2M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $0M | $0M | $0M | $0M |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $1M | $1M | $1M |
| Cash & Cash Equivalents | $0M | $1M | $1M |
| Total Liabilities | $3M | $2M | $0M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M |
| Total Shareholders' Equity | ($2M) | ($1M) | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VOGX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms